TABLE 2.
Rates of Emergency Hospital Admissions and Attendances for patients receiving ipinivo, pembrolizumab and ipilimumab
| In‐patient emergency admissions | A & E attendance | |||
|---|---|---|---|---|
| Within 30 days of first treatment date | ||||
| Ipinivo | 37% | 16% | ||
| Pembrolizumab | 17% | P < .0001 | 8% | P < .0001 |
| Ipilimumab | 24% | P = .013 | 9% | P < .0001 |
| Within 30 days of last treatment date | ||||
| Ipinivo | 55% | 19% | ||
| Pembrolizumab | 29% | P < .0001 | 14% | P = .33 |
| Ipilimumab | 40% | P < .0001 | 15% | P = .33 |
Note: The P‐value is comparing the percentage of ipinivo emergency inpatient admissions and A&E attendances with the percentage of emergency inpatient admissions and A&E attendances for pembrolizumab and ipilimumab. A&E attendances correspond to when patients attend A&E. Emergency inpatient admissions are when patients are admitted for unplanned care. There are many routes through which a patient can be admitted for emergency care, including managed routes such as via a General Practitioner, as well as being admitted following an A&E attendance.